Cargando…
Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer
BACKGROUND: To explore the maximum tolerated dose (MTD) and evaluate the safety of dose escalation using hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) concurrent with chemotherapy for unresectable stage III non-small cell lung cancer (NSCLC). METHODS: Fou...
Autores principales: | Zhang, Qin, Cai, Xu-Wei, Feng, Wen, Yu, Wen, Fu, Xiao-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783483/ https://www.ncbi.nlm.nih.gov/pubmed/35065627 http://dx.doi.org/10.1186/s12885-021-09099-3 |
Ejemplares similares
-
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023) -
Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
por: Donato, Vittorio, et al.
Publicado: (2013) -
Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost
por: Embring, Anna, et al.
Publicado: (2023) -
Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer
por: Hepel, Jaroslaw T., et al.
Publicado: (2012) -
Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial()()
por: Wang, Si-Yang, et al.
Publicado: (2018)